Drug repurposing: mebendazole as effective antitumor agent. Are we seeing the whole story? (2018)

Peer-Reviewed Study · Pavle Banovic; Srdjan Stankov; Nenad Vranjes et al. · 2018

Pavle Banovic et al., 2018: Banovic et al. tested mebendazole by oral and intraperitoneal routes in a hamster fibrosarcoma model and found no objective antitumour effect; the paper asks whether the repurposing literature is telling the whole story.

The results of this study showed absence of objective MZ antitumor effect on experimental fibrosarcoma.

Pavle Banovic et al., 2018: Banovic et al. tested mebendazole by oral and intraperitoneal routes in a hamster fibrosarcoma model and found no objective antitumour effect; the paper asks whether the repurposing literature is telling the whole story. Study type: experimental fibrosarcoma (BHK-21/C13 cells) in Syrian golden hamsters, 5 experimental and 2 control groups. N: hamsters, number not stated in the abstract. Country: Serbia (University of Novi Sad). Dose: 'the highest for the animal to survive during the experiment', value not stated in the abstract; routes oral and intraperitoneal; treatment started at day 10 after inoculation. Funder: not stated in the record. Declared conflicts: no COI statement in the record. Comparator: doxorubicin intraperitoneally (positive control) and olive oil orally (negative control). This is the negative animal study in the record. Bearing is recorded as SUPPORTS because the C6 claim as written asks for animal studies including negative ones; read as a statement that mebendazole shrinks tumours in animal models, this document contradicts it, and the summary and this note are the place that contrary result is held at full strength. Study type: animal.